Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a…
Indonesia seeks to preserve historic railway assets as part of global heritage
Gigawatts Are Announced. Megawatts Must Be Energized.
Noah Kangian Adds 100+ New Services to MSP Panel’s Indian SMM Panel Service List
Astra Security Named Best Autonomous Pentesting Tool of 2026